Rhythm Pharmaceuticals Reports Q2 2026 Results; RM-718 Phase 2 Data

What Happened
Rhythm Pharmaceuticals, Inc. (RYTM) announced its financial results for the quarter ended June 30, 2026 and simultaneously disclosed preliminary data from its ongoing Phase 2 trial of RM-718 in patients with acquired hypothalamic obesity. Both the press release reporting the quarterly results and the materials summarizing the RM-718 data were issued on August 4, 2026 and are furnished as exhibits to the Form 8-K. The presentation is also available on the company’s investor website.

Key Details

• Announcement and filings dated August 4, 2026 covering quarterly results for the period ended June 30, 2026 (Item 2.02).
• Regulation FD disclosure and presentation published summarizing preliminary Phase 2 RM-718 data in acquired hypothalamic obesity (Item 7.01 and Item 8.01).
• Press release and slides furnished as Exhibits 99.1 (earnings release), 99.2 (press release), and 99.3 (presentation); presentation posted at ir.rhythmtx.com.
• Materials describe preliminary clinical data (early-stage results); the company labeled these as preliminary and posted supporting slides for investor review.

Why It Matters
For investors, this 8-K provides both the company’s latest quarterly results (earnings/quarterly results disclosure) and an update on clinical progress for RM-718, a program that could affect Rhythm’s future valuation if later-stage data are positive. The published presentation and press releases let investors review the company’s financials and the preliminary trial data directly; because the RM-718 results are early-stage and described as preliminary, investors should treat them as informational rather than definitive clinical outcomes.